

1 **Integration of single cell omics with biobank data discovers *trans* effects**
2 **of *SREBF1* abdominal obesity risk variants on adipocyte expression of more than 100**
3 **genes**

4
5 Mihir G. Sukhatme¹, Asha Kar^{1,2}, Uma Thanigai Arasu³, Seung Hyuk T. Lee¹, Marcus Alvarez¹,
6 Kristina M. Garske¹, Kyla Z. Gelev¹, Sandhya Rajkumar¹, Sankha Subhra Das¹, Dorota
7 Kaminska^{4,5}, Ville Männistö^{6,7}, Hilkka Peltoniemi⁸, Sini Heinonen⁹, Ulla Säiläkivi¹⁰, Tuure
8 Saarinen¹⁰, Anne Juuti¹⁰, Kirsi H. Pietiläinen^{9,11}, Jussi Pihlajamäki^{4,12}, Minna U. Kaikkonen³,
9 Päivi Pajukanta^{1,2,13, *}

10
11
12 ¹Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
13 ²Bioinformatics Interdepartmental Program, UCLA, Los Angeles, CA, USA
14 ³A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
15 ⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
16 ⁵Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA,
17 Los Angeles, CA, USA
18 ⁶Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio,
19 Finland
20 ⁷Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland
21 ⁸Eira Hospital, Helsinki, Finland
22 ⁹Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of
23 Medicine, University of Helsinki, Helsinki, Finland
24 ¹⁰Department of Abdominal Surgery, Abdominal Center, Helsinki University Hospital and
25 University of Helsinki, Helsinki, Finland
26 ¹¹HealthyWeightHub, Endocrinology, Abdominal Center, Helsinki University Central Hospital
27 and University of Helsinki, Helsinki, Finland
28 ¹²Department of Medicine, Endocrinology and Clinical Nutrition, Kuopio University Hospital,
29 Kuopio, Finland
30 ¹³Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA,
31 USA
32 * Corresponding author ppajukanta@mednet.ucla.edu
33

34

35

36

37

38

39

40

41 **Abstract**

42 Given the fast-increasing prevalence of obesity and its comorbidities, it would be critical to
43 improve our understanding of the cell-type level differences between the two key human adipose
44 tissue depots, subcutaneous (SAT) and visceral adipose tissue (VAT), in their depot-specific
45 contributions to cardiometabolic health. We integrated cell-type level RNA- and ATAC-seq data
46 from human SAT and VAT biopsies and cell-lines to comprehensively elucidate transcriptomic,
47 epigenetic, and genetic differences between the two fat depots. We identify cell-type marker
48 genes for tissue specificity and functional enrichment, and show through genome-wide
49 association study (GWAS) and partitioned polygenic risk score (PRS) enrichment analyses that
50 the marker genes upregulated in SAT adipocytes have more prominent roles in abdominal
51 obesity than those of VAT. We also identify *SREBF1*, a master transcription factor (TF) of fatty
52 acid synthesis and adipogenesis, as specifically upregulated in SAT adipocytes and present in
53 numerous SAT functional pathways. By integrating multi-omics data from an independent
54 human cohort, we further show that the risk allele carrier status of seven abdominal obesity
55 GWAS variants in the *cis* region of *SREBF1* affects the adipocyte expression of 146 SAT
56 adipocyte marker genes in *trans*. We replicate this finding independently in the UK Biobank by
57 showing that the partitioned abdominal obesity PRSs of the *trans* gene sets differ by the regional
58 *SREBF1* risk allele carrier status. In summary, we discover the master TF, *SREBF1*, driving the
59 SAT adipocyte expression profiles of more than a hundred of adipocyte marker genes in *trans*, a
60 finding that indicates that human *trans* genes can be identified by integrating single cell omics
61 with biobank data.

62

63

64 **Abbreviations**

65 ASPC - Adipose stem and progenitor cell

66 ATAC - Assay for transposase accessible chromatin

67 AUC – Area under the curve

68 BMI - Body mass index

69 CCA - Canonical correlation analysis

70 CMD - Cardiometabolic disease

71 DE - Differential expression

72 DA - Differential accessibility

73 GWAS - Genome-wide association study

74 KOBS - Kuopio Obesity Surgery Study

75 LD - Linkage disequilibrium

76 LEC - Lymphatic endothelial cells

77 MASLD - Metabolic dysfunction-associated steatotic liver disease

78 MGSBT - Marker genes shared between the SAT and VAT tissues

79 MGSS - Marker genes specific to SAT

80 MGSV - Marker genes specific to VAT

81 NK - Natural killer cells

82 PCA - Principal component analysis

83 PRS - Polygenic risk score

84 RNA-seq - RNA-sequencing

85 RYSA - Roux-en-Y Gastric Bypass versus Single-Anastomosis Gastric Bypass

- 86 SAT - Subcutaneous adipose tissue
- 87 SMC - Smooth muscle cells
- 88 snRNA-seq - Single nucleus RNA-sequencing
- 89 *SREBF1* - Sterol regulatory element-binding transcription factor 1
- 90 T2D - Type 2 diabetes
- 91 TF - Transcription factor
- 92 UKB - UK Biobank
- 93 VAT - Visceral adipose tissue
- 94 WHRadjBMI - Waist-hip ratio adjusted for BMI
- 95
- 96

97 **Introduction**

98 Subcutaneous (SAT) and visceral adipose tissue (VAT) are the two key fat depots in humans.
99 SAT has many important functional roles, including lipogenesis, lipolysis, hormonal, and
100 endocrine functions, and SAT is also the fat depot that expands most in the presence of
101 obesity^{1,2}. Efficient adipogenesis (i.e. differentiation of preadipocytes to adipocytes) is critical
102 for this expansion and buffering against lipotoxicity and low-grade inflammation, the hallmark
103 of obesity^{1,3}. VAT, i.e. the deeper intra-abdominal fat that lines internal organs, has a lesser
104 capacity to expand in the presence of obesity and is even more prone to pro-inflammatory
105 profiles than SAT^{1,4,5}. It has been postulated that efficient SAT adipogenesis is likely relevant for
106 this VAT inflammation as well⁶; however, the actual tissue- and cell-type-specific functions of
107 VAT are not comprehensively understood in humans⁴, likely partly reflecting the practical
108 difficulties in obtaining human VAT samples. Thus, it would be crucial to advance our
109 understanding of the cell-type level transcriptional differences between these two human main
110 fat depots and how they relate to depot-specific contributions to cardiometabolic health and
111 disease.

112
113 Previous bulk tissue RNA-seq studies have successfully identified *cis* regulatory variants and
114 their targets genes in local *cis* expression quantitative trait locus (*cis*-eQTL) analyses⁷⁻¹⁰
115 Furthermore, SAT bulk tissue analysis have detected abdominal obesity associated co-
116 expression networks, regulated by transcription factors (TFs), such as *TBX15*¹¹, suggesting
117 that TFs regulate cardiometabolic trait -associated gene expression in fat depots in *trans*.
118 However, identification of *trans* regulatory variants and their target genes has been
119 challenging in SAT and VAT due to the extensive multiple testing issue of the *trans*-eQTL

120 analysis and small samples sizes of SAT and VAT data available for study, which has
121 hampered powerful enough *trans*-eQTL discovery. Accordingly, very few *trans* signals have
122 been identified^{12,13} and replicated in SAT or VAT. Thus, it is not well understood how variant
123 level differences in TFs, especially in disease-connected GWAS effect alleles, contribute to
124 downstream target genes in *trans* in bulk tissues, and even less is known about single cell level
125 *trans* regulatory variants their target genes in SAT or VAT.

126

127 To advance *trans* gene discovery, we first performed dual-tissue single nucleus RNA-sequencing
128 (snRNA-seq) from the same individuals' SAT and VAT biopsies, which identified the unique
129 cell-type marker genes in each fat depot for the main cell-types between SAT and VAT. We then
130 separated these markers into those specific to SAT, specific to VAT, and shared between the two
131 tissues. This design helped us identify a key adipose tissue TF, Sterol Regulatory Element
132 Binding Transcription Factor 1 (*SREBF1*)^{14,15}, among the unique SAT marker genes, present in
133 87% of functional pathways of SAT adipocytes, suggesting that it exhibits an important *trans*
134 regulatory role. Next, we found regional abdominal obesity -associated GWAS variants landing
135 in SAT adipocyte open chromatin in the *cis* region of *SREBF1*. Using a large set of SAT snRNA-
136 seq data from an independent human cohort, we then identify more than one hundred *SREBF1*
137 target genes, the adipocyte expression of which differ by the *SREBF1* abdominal obesity GWAS
138 risk variant carrier status. Finally, we discover by building regional PRSs for the *SREBF1 trans*
139 target genes in the independent UK Biobank, that their abdominal obesity PRSs differ by the risk
140 allele carrier status of the *SREBF1* abdominal obesity GWAS variants, providing thus
141 converging evidence to the single cell level data about the *trans* effects of this key TF. Overall,

142 our study integrate single cell omics and biobank data to identify a master SAT TF and a large
143 number of its *trans* regulated adipocyte genes for abdominal obesity.

144

145

146 **Methods**

147 **Study cohorts**

148 **KOBS cohort**

149 In our dual tissue study design, we analyzed both subcutaneous (SAT) and visceral adipose
150 tissue (VAT) single nucleus RNA-sequencing (snRNA-seq) data from matching seven Finns
151 with obesity (2 females and 5 males) from the Kuopio Obesity Surgery Study (KOBS)
152 cohort^{16,17}. This cohort comprises individuals with severe obesity (BMI>30 kg/m²) who
153 underwent bariatric surgery, and whose SAT and VAT biopsies were both collected at the
154 surgery baseline for these single-cell level omics analyses. The mean BMI and age of these seven
155 individuals are 38.03 kg/m² (SD=1.76) and 54.11 years (SD=2.03). All participants provided
156 informed written consent. The study was approved by the local ethics committee. All research
157 conformed to the principles of the Helsinki Declaration.

158

159 **UKB cohort**

160 For our genome-wide association study (GWAS) enrichment, polygenic risk score (PRS), and
161 partitioned heritability analysis, we used the UK Biobank (UKB)¹⁸. Given that our single-cell
162 level data are of European origin, we only included the unrelated European-origin UKB
163 participants (n=391,701) in our analysis. As described previously^{18,19}, the genotype data for these
164 individuals were generated using two highly overlapping genotype arrays, Applied Biosystems
165 UK BiLEVE Axiom Array (807,411 markers) and Applied Biosystems UK Biobank Axiom
166 Array (825,927 markers)¹⁸, and imputed using the Haplotype Reference Consortium (HRC),
167 UK10K, and 1000 Genomes panels¹⁹. Data from UKB were accessed under application 33934.

168

169 **RYSA cohort**

170 Finnish individuals with obesity were recruited for the RYSA bariatric surgery study at the
171 Helsinki University Hospital, Helsinki, Finland, as described previously²⁰. In this study, we used
172 the operation time-point SAT snRNA-seq data from 68 RYSA participants with obesity to test
173 whether adipocyte expression of SAT adipocyte marker genes is affected in *trans* by the risk
174 allele carrier status of seven WHRadjBMI GWAS variants in the *SREBF1 cis* region. The RYSA
175 study was approved by the Helsinki University Hospital Ethics Committee, and all participants
176 provided a written informed consent. All research conformed to the principles of the Helsinki
177 Declaration.

178

179 **Genotype quality control and imputation in the KOBS and RYSA cohorts**

180 We genotyped DNAs of KOBS participants using the Infinium Global Screening Array-24 v1
181 (Illumina). We performed quality control (QC) on the genotype data using PLINK v1.9²¹ by
182 excluding individuals with missingness >2% and removing unmapped, strand ambiguous, and
183 monomorphic SNPs in addition to variants with missingness >2% and Hardy-Weinberg
184 Equilibrium (HWE) p -value < 10^{-6} . We further imputed biological sex using the ‘--sex-check’
185 function in PLINK v1.9²¹ and cross-checked with the reported sex of each individual.

186

187 We performed genotype imputation against the HRC reference panel version r1.1 2016²² on the
188 Michigan imputation server after removing duplicate variants and variants with allele mismatch
189 with the reference panel. Strand flips or allele switches needed to match the reference panel were
190 performed on the server before haplotype phasing using Eagle v2.4²³ and genotype imputation

191 using minimac4²⁴. We performed QC on the imputed genotype data by removing SNPs with
192 imputation score $R^2 < 0.3$ and HWE p -value $< 10^{-6}$ for the downstream analyses.

193

194 We genotyped the RYSA participants' DNAs using the Infinium Global Screening Array-24 v1
195 (Illumina). Genotype data QC, imputation, and post-imputation QC were performed for the
196 RYSA cohort as described above.

197

198 **Nuclei isolation in VAT biopsies from the KOBS cohort**

199 To isolate nuclei from the snap-frozen VAT biopsies from the KOBS participants, we first
200 combined and minced the VAT samples in a petri dish over dry ice and immediately transferred
201 the minced tissue into a 500 μ l chilled 0.1X Lysis Buffer consisting of 10 mM Tris-HCl, 10 mM
202 NaCl, 3 mM MgCl₂, 0.1% Tween-20, 0.1% IGEPAL CA-630, 0.01% Digitonin, 1% BSA, 1 mM
203 DTT, and 1 U/ μ L RNase inhibitor. After a 15-minute incubation period, the lysate mixed with a
204 500 μ l chilled Wash Buffer containing 10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl₂, 1% BSA,
205 0.1% Tween-20, 1 mM DTT, and 1 U/ μ L RNase inhibitor was passed through a 70 μ m Flowimi
206 Cell Strainer into a 2 ml tube. Nuclei were centrifuged at 500 rcf for 5 minutes at 4°C and the
207 supernatant was removed without disrupting the nuclei pellet, followed by a resuspension in a 1
208 ml chilled Wash Buffer. Nuclei were passed through a 40 μ m Flowimi Cell Strainer into a 2 ml
209 tube and centrifuged at 500 rcf for 5 minutes at 4°C. We removed the supernatant without
210 disrupting the nuclei pellet and resuspended in a 30 μ l chilled Diluted Nuclei Buffer containing
211 1X Nuclei Buffer (10x Genomics), 1 mM DTT, and 1 U/ μ l RNase inhibitor. We measured the
212 concentration and overall quality of the nuclei using Countess II FL Automated Cell Counter
213 after staining with trypan and DAPI and used the Single Cell Multiome ATAC + Gene

214 Expression Reagent Kit (10x Genomics) for the joint snRNA- and snATAC-seq library
215 construction. We analyzed the quality of cDNA and libraries using Agilent Bioanalyzer and
216 sequenced the libraries on an Illumina NovaSeq X Plus (snRNA) and Next seq 500 (snATAC)
217 with a target sequencing depth of 400 million read pairs for both snRNA- and snATAC-seq.

218

219 **Nuclei isolation in SAT biopsies of the KOBS and RYSA cohorts**

220 We performed SAT snRNA-seq experiments on the snap-frozen SAT biopsies from the KOBS
221 participants, as previously described¹¹. Briefly, we first pooled approximately 100 mg of each
222 biopsy and isolated nuclei from the pooled biopsies as described earlier¹¹. Next, we measured the
223 concentration and overall quality of the nuclei using Countess II FL Automated Cell Counter
224 after staining with trypan and DAPI and used the Single Cell 3' Reagent Kit v3.1 (10x
225 Genomics) for the library construction. We analyzed the quality of cDNA and gene expression
226 library using Agilent Bioanalyzer and sequenced the library on an Illumina NovaSeq SP with a
227 target sequencing depth of 600 million read pairs.

228

229 In this study, we used the operation time-point SAT snRNA-seq data from 68 participants with
230 obesity of the RYSA cohort, generated as part of the full RYSA cohort, by randomly pooling 8
231 SAT samples/batch for nuclei isolation. We isolated nuclei and constructed libraries for SAT
232 snRNA-seq from each batch as described above and sequenced libraries from all batches
233 together on an Illumina NovaSeq S4 with a target sequencing depth of 400 million read pairs per
234 batch.

235

236 **Processing of the SAT snRNA-seq data from the RYSA cohort**

237 We aligned the raw snRNA-seq data in a FASTQ format file for each batch against the GRCh38
238 human genome reference and GENCODE v42 annotations²⁵ using STAR v2.7.10b²⁶ with the '--
239 soloFeatures GeneFull' option to account for full pre-mRNA transcripts. We evaluated the
240 quality of the raw and mapped snRNA-seq data using FastQC. Next, we used DIEM v2.4.0²⁷ to
241 remove empty droplets and droplets with high amounts of ambient RNA. We set droplets with
242 UMI<500 as debris, used $k=50$ for the initialization step with k-means clustering, and otherwise
243 used the default parameters. After the clustering step, we removed clusters of highly
244 contaminated droplets characterized by low average UMIs, low average number of unique genes
245 detected (nFeatures), high percentage of reads mapped to the mitochondrial genome (%mito),
246 and high number of mitochondrial and ribosomal genes as top expressed features. Next, we used
247 Seurat v4.3.0.1²⁸ to remove low-quality droplets with UMI<500, nFeatures<200, %mito>10%,
248 and spliced read fraction≥75%, log-normalize gene counts using the 'NormalizeData' function,
249 identify top 2,000 variable genes excluding mitochondrial and ribosomal genes using the
250 'FindVariableFeatures' function, scale the normalized gene counts to mean 0 and variance 1
251 using the 'ScaleData' function, perform principal component analysis (PCA) using the
252 'RunPCA' function, and cluster the nuclei with a standard Louvain algorithm, first 30 PCs, and a
253 resolution of 0.5. For the remaining nuclei, we removed contaminated counts using DecontX²⁹
254 with the previously removed low-quality nuclei as the background and the Seurat cluster
255 assignment as the 'z' and removed additional low-quality nuclei with UMI<500, UMI>30,000,
256 nFeatures<200, and %mito>10% based on the remaining clean counts. To identify the
257 originating participant of each nucleus, we used demuxlet from popsicle software tool³⁰ with '--
258 min-MQ 30' and high-quality imputed genotype data. We only included nuclei classified as a
259 singlet and assigned the best matching participant to identify the originating participant for each

260 nucleus. Next, we used DoubletFinder³¹ to identify and remove any remaining doublets. As
261 DoubletFinder requires predicted number of doublets in each dataset, we performed pN-pK
262 parameter sweeps on a subset of 10,000 nuclei to select pN of 0.25 and the most optimal pK
263 value maximizing mean-variance normalized bimodality coefficient for each batch, as previously
264 recommended²⁷.

265

266 After performing the QC, we used Seurat v4.3.0.1²⁸ to merge all remaining high-quality droplets
267 from the batches and subset for nuclei originating from operation time-point samples of the 68
268 participants from the RYSA cohort included in this study. In the subset, we kept only the genes
269 with at least 3 raw counts in at least 3 nuclei²⁹ and performed gene count normalization, variable
270 gene identification, data scaling, and PCA, as described above. To account for variation in gene
271 expression driven by batch effect, we used Harmony v1.0.3³² to integrate on batch and clustered
272 the nuclei with a standard Louvain algorithm, first 30 reductions from Harmony, and a resolution
273 of 0.5. Cell-type annotations were performed using SingleR v1.8.1³³, as described above, with
274 the SAT single-cell and snRNA-seq data from the previously published adipose tissue atlas by
275 Emont et al. as a reference³⁴.

276

277 **Processing of the SAT VAT snRNA-seq data from the KOBS cohort**

278 We aligned the VAT and SAT snRNA-seq data from the seven KOBS biopsies to the GRCh38
279 human genome reference with Ensembl annotations using CellRanger-arc -count v2.0.0³⁵ and
280 CellRanger -count v6.1.1³⁵ for VAT and SAT, respectively. As the VAT sequencing from the
281 seven KOBS VAT biopsies was generated using the 10x Genomics Multiome platform, we
282 simultaneously profiled RNA and ATAC in each cell. We subset the data to include the nuclei

283 passing the QC for both RNA and ATAC, as recommended by CellRanger-arc, while only
284 including the VAT snRNA-seq data in the downstream analyses of this study. The KOBS SAT
285 snRNA-seq data were generated as a single modality and processed using the same reference
286 (GRCh38 human genome) but with the base software for CellRanger. Similarly to VAT, we only
287 included the nuclei from SAT that passed the recommended filtering from CellRanger. For the
288 remaining SAT and VAT nuclei, we separately further filtered out those containing ambient
289 reads using DIEM²⁷ through the removal of droplets from a debris cluster that reflected high
290 amounts of background RNA or low levels of nuclear RNA. To remove genetic doublets and
291 demultiplex the KOBS VAT Multiome samples and SAT snRNA-seq samples back to their
292 individuals of origin, we ran demuxlet³⁰ against the imputed genotype data of the individuals.
293 We removed all SAT and VAT cells that were not classified as singlets. We then ran DecontX²⁹
294 to remove contaminated reads within each droplet and filtered out nuclei with high levels of
295 ambient RNA, keeping those with UMIs over 200 and mitochondrial read percentage < 10%.
296 These QC processes resulted in 3,216 nuclei for VAT and 3,516 nuclei for SAT from the same
297 individuals.

298

299 **Integration and clustering of SAT and VAT snRNA-seq data from the KOBS cohort**

300 To find differences between SAT and VAT cell-type level gene expression from the KOBS
301 biopsy samples, we performed integration between the tissues using Seurat v4.3.0²⁸. The count
302 data for nuclei from each tissue were first log-normalized using the NormalizeData function of
303 Seurat²⁸, with the default scaling factor of 10,000. Using these normalized count data, the top
304 2000 variable genes per tissue were calculated using the FindVariableFeatures function.
305 Afterwards, we integrated the two tissues using canonical correlation analysis (CCA) with the

306 IntegrateData function of Seurat²⁸. Following integration, the normalized read counts were
307 scaled with a mean of 0 and variance of 1. In the integrated samples with a total of 6,732 cells
308 from across the SAT and VAT snRNA-seq data, we performed PCA and identified clusters using
309 30 PCs and a resolution of 0.8.

310

311 **SnRNA-seq cell-type assignment and unique marker gene identification in the KOBS SAT** 312 **and VAT biopsy samples**

313 We used SingleR v2.0.0³³ with a previously published human single-cell adipose atlas³⁴ as a
314 reference to annotate the data at the individual cell level³⁶. We ran the FindAllMarkers function
315 in Seurat²⁸ using *only.pos* = TRUE and *min.cells.group*=50 to identify marker genes of each cell-
316 type. We only included cell-types that consisted of at least 50 nuclei from the integrated tissues.
317 P-values were adjusted for multiple testing using the Bonferroni approach. To identify marker
318 genes unique per cell-type, we removed genes detected as marker genes (*padj*<0.05) for multiple
319 cell-types. These marker genes are shown in Supplementary Table 1.

320

321 **Tissue-specific marker gene identification**

322 To find differences in the expression profiles of the three most prevalent SAT and VAT cell-
323 types (adipocytes, macrophages, and adipose stem and progenitor cells (ASPC)) in the KOBS
324 cohort, we identified three separate sets of cell-type marker genes. These three sets comprised
325 cell-type marker genes specific to SAT (MGSS), VAT (MGSV), and shared between the tissues
326 (MGSBT). We identified tissue-specific markers using the FindMarkers function of Seurat²⁸,
327 using a log₂ fold change threshold of ≥ 0 , to compare the SAT and VAT data of each cell-type. In
328 this tissue-specific marker gene identification, we only included the genes identified as unique

329 markers for each cell-type above. We adjusted p-values for multiple testing using $FDR < 0.05$ for
330 the total number of cell-type-specific markers from above. Using this adjustment method, we
331 identified genes that are not only cell-type-specific but also show differential expression (DE)
332 between VAT (MGSV) and SAT (MGSS). We also identified a third group of marker genes for
333 each cell-type, i.e., those that showed no significant DE ($FDR > 0.05$) between SAT and VAT.
334 We classified these as marker genes shared between the SAT and VAT tissues (MGSBT).
335 Overall, this resulted in 9 cell-type marker gene sets, i.e., three per cell-type (macrophages,
336 adipocytes, and ASPC) with no overlap between them. These 9 sets are listed in Supplementary
337 Table 2.

338

339 **Identification of enriched functional pathways**

340 After identifying the 9 sets of cell-type marker genes, as described above, we ran WebGestalt³⁷
341 to functionally characterize each set, using all genes with non-zero expression in at least two
342 cells in the cell-type³⁴ irrespective of the tissue origin, as the background. For each set, we tested
343 for significant ($FDR < 0.05$) overrepresentation of genes from Gene Ontology (GO) biological
344 processes, cellular components, and molecular functions. We then identified the top pathway
345 genes (i.e. the genes that appeared in >1 significantly enriched pathways) by ranking each gene
346 by the number of times it appeared in the identified pathways.

347

348 **GWAS enrichment analysis of the cell-type marker genes**

349 We assessed the 9 sets of tissue-specific and tissue-shared cell-type marker genes for significant
350 enrichments of genetic associations with BMI, WHRadjBMI, T2D, and MASLD using
351 MAGENTA v2.4 (Meta-Analysis Gene-set Enrichment of variant Associations)³⁸.

352

353 We first downloaded publicly available European-only GWAS summary statistics for T2D³⁹,
354 while for WHRadjBMI and BMI, we used the UKB GWAS data we generated, as described
355 above. For every outcome, we then used the summary statistics to generate association scores for
356 each gene within the gene set based on the p-values of all variants within a 500kb upstream and
357 downstream window. Gene score-cutoff tests using the 75th percentiles of the scores of all genes
358 as cutoffs were performed to evaluate enrichment. While MAGENTA³⁸ filters out genes near one
359 another, we retained all genes per set in our analyses due to our small gene set sizes.

360

361 **Construction of marker gene -based regional and genome-wide PRSs for abdominal**
362 **obesity, BMI, and type 2 diabetes in UKB**

363 We built both marker gene -based regional and genome-wide PRSs for waist-hip ratio adjusted
364 for BMI (WHRadjBMI), body mass index (BMI), and type 2 diabetes (T2D) for all unrelated
365 Europeans from UKB¹⁸. In our analysis, WHRadjBMI was used as a well-established proxy for
366 abdominal obesity¹¹. The genome-wide PRSs for these traits were constructed using all SNPs
367 (see below), whereas the regional PRSs for each trait were created using the *cis* regional SNPs
368 (gene \pm 500kb) of each of the autosomal marker gene sets separately (MGSBT, MGSS, and
369 MGSV) for the three main cell-types (adipocytes, macrophages, and ASPCs). We excluded the
370 set that contained shared SAT/VAT macrophage marker genes as it comprised only 9 genes, and,
371 therefore, it remained too small for reliable regional PRS building given the technical issues with
372 overfitting in PRS⁴⁰. As WHRadjBMI is a highly sex-specific trait¹¹, we also built the regional
373 WHRadjBMI PRSs for males (n= 88,988) and females (n=104,614) separately. Thus, in addition

374 to the genome-wide PRSs, we constructed 24 regional PRSs for WHRadjBMI and 8 regional
375 PRSs for T2D and BMI, respectively.

376

377 **Construction of WHRadjBMI and BMI PRSs**

378 To construct the WHRadjBMI and BMI PRSs, we randomly selected 50% of the unrelated
379 Europeans from UKB (n=195,863) to generate GWAS summary statistics as the base data for the
380 PRS, and applied the PRS model in the remaining 50% of the cohort (i.e., the target group). For
381 the GWASs, the data were filtered to only retain variants with MAF >1% and INFO>0.8. We
382 also removed individuals with >1% of their genotypes missing or extreme heterozygosity, as
383 well as variants missing in >1% of the subjects or violating Hardy-Weinberg equilibrium from
384 the genotype data target group⁴¹. We conducted the GWASs of WHRadjBMI and BMI using
385 linear-mixed model approach of BOLT-LMM v2.3.6²³, with age, age², sex, the top 20 genetic
386 PCs, testing center, and genotyping array as covariates, where we applied a rank-based inverse
387 normal transformation for each outcome. For WHRadjBMI, given the sex-specificity of the
388 outcome^{11,42,43}, we normalized twice, first in all individuals, and then for males and females
389 separately. Next, we fit the PRS models and computed the PRSs for WHRadjBMI and BMI for
390 the individuals in the target group using the split-validation mode from lassosum⁴⁴ (n=193,602)
391 and the filtered GWAS summary statistics as the base data for the PRS models.

392

393 **Construction of T2D PRSs**

394 To construct the T2D PRSs, we used the publicly available T2D GWAS summary statistics of
395 Europeans without UKB from the DIAGRAM Consortium⁴⁵ as the base data. We built the PRS
396 models using the target group genotype data employing PRScs⁴⁶, with the provided LD matrix

397 from the Europeans in the 1000 Genomes Project as the LD reference, and applied the models to
398 the target group using PLINK.

399

400 **Calculating the explained variance in the trait by the PRSs**

401 We calculated the incremental variance explained (R^2) in the trait against a null model containing
402 the covariates of age, age², the top 20 genetic PCs, testing center, genotyping array, and sex
403 using lassosum⁴⁴. For T2D, we calculated a delta AUC, similarly to the incremental variance
404 from above.

405

406 We evaluated the significance of each regional PRS by ranking the observed incremental R^2 or
407 delta AUC against the incremental R^2 /delta AUC of 10,000 PRSs similarly built from the *cis*
408 regional variants of random gene sets of the same size as in the regional PRS set, using all
409 expressed genes (counts \geq 1 in at least 2 nuclei)³⁴ in the cell-type of interest as a background.
410 The P-value was defined as the number of permutations in which the R^2 /delta AUC is larger than
411 the calculated PRS divided by 10,000.

412

413 **Partitioned heritability assessment of PRS-enriched gene sets**

414 We performed a partitioned heritability analysis with LD Score regression (LDSC)^{47,48} to assess
415 the genes with WHRadjBMI R^2 enriched PRSs for enrichment in the WHRadjBMI heritability
416 relative to the genome, similarly as in Finucane et al.⁴⁸. Briefly, we used LDSC to estimate the
417 LD scores from all SNPs in the genome, as well as from all SNPs residing with the *cis* regions of
418 each PRS-enriched gene set. Scores were constructed in 76,758 randomly selected, unrelated
419 Brits from UKB (35,257 males, 41,501 females) for computational efficiency, and as in Finucane

420 et al.⁴⁸, we only included SNPs with MAF>5% for the analysis. We then used the same
421 WHRadjBMI GWAS summary statistics as in the PRS analysis to compute the WHRadjBMI
422 heritability of the genome and marker gene annotations and test each marker annotation for
423 significant ($p<0.05$) heritability enrichment, defined as the proportion of heritability divided by
424 the proportion of the genome from the annotation⁴⁸.

425

426 **Longitudinal RNA- and ATAC-sequencing during human SAT primary preadipocyte** 427 **differentiation**

428 We previously performed a longitudinal adipogenesis experiment using human SAT primary
429 preadipocytes and generated longitudinal bulk RNA- and ATAC-seq data on samples collected at
430 the 0 day (0d), 1d, 2d, 4d, 7d, and 14d timepoints, with 4 isogenic replicates per timepoint, as
431 described earlier^{7,49}. Peaks from the ATAC-seq were filtered to remove blacklisted regions and
432 identify consensus peaks, as described in detail previously⁷.

433

434 **Differential expression (DE) analysis across six adipogenesis time points**

435 We examined the longitudinal expression patterns of the top pathway-enriched genes from the
436 adipocyte MGSS set ($n=43$ genes) using ImpulseDE2 v0.99.10⁵⁰. We used the runImpulseDE2
437 function with default parameters and *boolCaseCtrl*=FALSE, *boolIdentifyTransients*=TRUE, and
438 *scaNProc*=1. P-values were corrected for multiple testing using FDR<0.05. As the adipogenesis
439 experiment was conducted in SAT preadipocytes, we only ran this DE analysis for genes in the
440 adipocyte MGSS set.

441

442 **Identification of longitudinally co-expressed clusters of adipocyte pathway genes and their**
443 **regulators during human adipogenesis**

444 To search for longitudinal co-expression patterns among the adipocyte pathway genes across
445 human adipogenesis, we ran DPGP v0.1⁵¹ to cluster genes by their expression trajectories. We
446 ran DPGP with the timepoint data of the adipogenesis experiment described above and only
447 included the genes that we identified as significantly longitudinally DE (FDR<0.05) during
448 human adipogenesis from ImpulseDE2⁵⁰ and expressed across adipogenesis (n=42).

449

450 **Identification of co-accessible peaks during human adipogenesis within the *cis* region of**
451 ***SREBF1***

452 To identify co-accessible peaks in the *SREBF1 cis* region during human adipogenesis, we used
453 the longitudinal ATAC-seq data from the human SAT primary preadipocyte differentiation
454 experiment described above. We first identified SAT adipocyte peaks within ± 500 kb of
455 *SREBF1*, a key SAT adipocyte marker gene. To determine temporal differential accessibility
456 (DA) of these SAT peaks and identify clusters of longitudinally co-accessible peaks, we ran
457 ImpulseDE2⁵⁰ as described above on the accessibility counts for the peaks, subset the data to the
458 peaks passing an FDR threshold<0.05, and then clustered the DA peaks (n=120) using DPGP⁵¹,
459 as described above. We only included the clustered peaks that passed a cluster assignment
460 threshold of probability>0.9.

461

462 **Identification of WHRadjBMI GWAS variants within the longitudinally co-accessible SAT**
463 **adipocyte peaks in the *SREBF1 cis* region**

464 We next investigated the 5 longitudinally co-accessible SAT adipocyte peaks discovered in the
465 SAT adipogenesis experiment within the *cis* regions of *SREBF1* for WHRadjBMI GWAS
466 variants. Accordingly, we overlapped the positions of the genome-wide significant ($p < 5 \times 10^{-8}$)
467 WHRadjBMI GWAS variants using the summary statistics from a previously published
468 extensive WHRadjBMI GWAS of the GIANT–UKB meta-analysis⁵² with the positions of the
469 co-accessible SAT adipocyte peaks.

470

471 **Identification of adipocyte MGSS genes by risk allele status of the WHRadjBMI GWAS**
472 **variants in the *SREBF1* region**

473 We tested whether the risk allele carrier status of the seven WHRadjBMI GWAS variants
474 residing in the longitudinally co-accessible SAT peaks in the *SREBF1* region affects the SAT
475 adipocyte expression of *SREBF1* and other SAT adipocyte markers genes in *trans* using RYSA
476 SAT adipocyte snRNA-seq data. Briefly, for each variant, we labeled each individual from the
477 RYSA cohort with zero copies of the GWAS trait-increasing allele as “non-carriers” and those
478 with one or two copies of the trait-increasing allele as “carriers,” and then labelled each
479 individual cell in the cohort as coming from a “carrier” or a “non-carrier” individual. We subset
480 the SAT snRNA-seq data to adipocytes and ran the FindMarkers function in Seurat²⁸ with
481 `logfc.threshold = 0` between cells labeled “carriers” and “non-carriers” while only testing the
482 adipocyte MGSS gene set and adjusting the p-values for multiple testing using $FDR < 0.1$. We
483 repeated this for each of the seven SNPs. For each *trans* gene set, we built module scores using
484 the AddModuleScore function in Seurat v4.3.0²⁸ in SAT adipocytes from the RYSA cohort to
485 determine the average expression across all adipocytes between carriers and non-carriers.

486

487 **Identification of adipogenesis open chromatin peaks by cell-type**

488 To identify upregulated and shared peaks at the preadipocyte and adipocyte stages of human
489 adipogenesis, we ran DESeq2⁵³ on the raw peak count data generated using ATAC-seq at the day
490 0 and 14 time points in the SAT adipogenesis experiment described above. Peaks with a
491 $\log_2FC > 0.1$ and Bonferroni adjusted P (p_{adj}) < 0.05 were classified as upregulated in
492 preadipocytes, while the peaks with a $\log_2FC < -0.1$ and $p_{adj} < 0.05$ were classified as upregulated
493 in adipocytes. The remaining peaks were classified as shared between the human preadipocytes
494 and adipocytes.

495

496 **Construction of abdominal obesity PRSs in UKB for the adipocyte marker genes affected**
497 **by the seven regional *SREBF1* variants in *trans***

498 To investigate the abdominal obesity risk of the regional variants in the *trans* gene sets, the
499 adipocyte expression of which is up- or downregulated by the *SREBF1* variant carrier status, we
500 constructed partitioned PRSs using the *cis* regional SNPs of these *trans* gene sets. The PRSs
501 were built separately for each up/downregulated *trans* gene set for the seven SNPs, resulting in
502 14 total unique PRS sets. As abdominal obesity risk differs by sex^{42,43}, we analyzed these
503 partitioned abdominal obesity PRSs in all individuals, females, and males separately. Due to the
504 small region sizes and to allow for fine-grained control of the SNPs comprising each PRS, we
505 used a clumping and thresholding (C+T) approach with PLINK v1.9 for the PRS construction,
506 with the same GWAS summary statistics for WHRadjBMI described above, as the base data. We
507 partitioned the remaining 50%, not used for the GWAS, into two cohorts, a 30% test group
508 (n=115,120) for performing the LD clumping and learning the optimal thresholding parameter,
509 and a 20% validation group (n=76,758) to apply the learned PRS model and perform

510 downstream analyses. We performed QC on the test and validation genotype data, similarly as
511 described above.

512

513 To build the partitioned abdominal obesity PRSs, we first performed LD clumping on the full
514 genotype data of the test groups with PLINK v1.9 using R^2 of 0.2 and window size of 250 kb,
515 and built the PRSs from the independent SNPs passings p-value thresholds ranging from 5×10^{-8}
516 to 0.5 to empirically determine the p-value threshold that maximizes the incremental variance
517 explained in WHRadjBMI in the test group. Next, for each *trans* gene set, we identified all C+T
518 SNPs that landed in the adipocyte upregulated open chromatin peaks (described earlier), using
519 the empirically determined p-value thresholds of $p < 0.05$, $p < 0.005$, and $p < 0.1$ for all individuals,
520 females, and males, respectively. To avoid direct *SREBF1 cis* effects on the abdominal obesity
521 risk, we removed the seven SNPs in the *SREBF1* region as well as any C+T SNPs in LD
522 ($R^2 > 0.1$) with any of these seven SNPs from these partitioned PRS analyses. We computed PRSs
523 for the sets that contained ≥ 5 valid SNPs. As explained before, the incremental variance (R^2)
524 was calculated for each PRS and compared against 10,000 permuted PRSs built from the same
525 numbers of C+T SNPs.

526

527 After computing individual level WHRadjBMI PRSs, we compared the polygenic risk, i.e., the
528 PRS magnitudes, in the regional PRSs of the *trans* gene sets between the *SREBF1* variant
529 carriers and non-carriers. First, we classified individuals in the UKB PRS cohort into “carriers”
530 or “non-carriers” in the same way as in the RYSA cohort. Next, we performed a two-sided
531 Wilcoxon test between the WHRadjBMI PRSs of the carriers and non-carriers within each group
532 while correcting for multiple testing using Bonferroni.

533 **Results**

534 **Study design**

535 The summary of the study design is shown in Supplementary Figure 1. Briefly, by first
536 identifying cell- and tissue-type expression profiles that drive functional differences between the
537 two key human fat depots, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
538 and genetic enrichments of these SAT and VAT -specific genes for abdominal obesity, we
539 discovered a transcription factor (TF) gene preferentially involved in numerous functional SAT
540 pathways over VAT. We then further investigated the cell-type level regulatory mechanisms of
541 this TF, and discovered that the regional abdominal obesity GWAS variants of this TF affect the
542 adipocyte expression of tens of SAT adipocyte marker genes in *trans* in the independent RYSA
543 cohort. Finally, we confirmed the identified *trans* effects of the TF variants by comparing the
544 partitioned regional PRSs of the *trans* genes by their risk allele carrier status at the biobank level
545 (Figure 1a).

546

547 **Marker gene analysis reveals distinct differences between SAT and VAT in cell-type level** 548 **expression profiles**

549 To elucidate cell-type level functional differences between SAT and VAT, the two main human
550 fat depots¹, we first investigated SAT and VAT gene expression profiles at the cell-type
551 resolution using SAT and VAT biopsies from the same individuals (Figure 1b-c). These dual
552 tissue fat depot data from the same individuals, which reduce confounding by phenotypic
553 differences between the donors of the SAT and VAT biopsies, enabled us to identify unique SAT
554 and VAT cell-type marker genes, or genes that are differentially upregulated in only one cell-
555 type, and also unique to each adipose tissue depot in their marker gene status (see Methods).

556 Figure 1d shows the adipocyte cell-type markers distributed by tissue specificity. Supplementary
557 Table 1 shows the identified unique cell-type marker genes for all SAT and VAT cell-types after
558 integrating the single nucleus level data of the two tissues. As small differences often drive
559 depot-specific gene and functional patterns⁴², we sought to study not only differences in
560 expression between the depots but also shared transcriptional profiles, as this may elucidate the
561 connection and shared characteristics between the tissues. Thus, from each cell-type marker set,
562 we identified sets of unique marker genes specific to each tissue and shared across the two,
563 resulting in 3 sets: marker genes specific to SAT (MGSS), marker genes specific to VAT
564 (MGSV), and marker genes shared between tissues (MGSBT) (Supplementary Table 2). We
565 focused our analyses on the three major shared cell-types between SAT and VAT, i.e., adipose
566 stem and progenitor cells (ASPCs), adipocytes, and macrophages due to their functional pathway
567 enrichments (see below) and highest number of nuclei available across the two tissues. The
568 MGSS sets contained 244, 208, and 250 unique cell-type marker genes for ASPCs, adipocytes,
569 and macrophages; the MGSV sets 131, 225, and 224; and the MGSBT sets 112, 155, and 9,
570 respectively (Supplementary Table 2).

571

572 **Shared and tissue-specific marker genes are enriched for genetic signals of obesity and** 573 **related CMDs**

574 As both adipose tissue depots are known to be impacted by obesity and related disorders^{2,4,5,54},
575 we first examined these marker gene sets for GWAS variant enrichments of obesity and related
576 CMDs. Accordingly, we tested the variants in the *cis* regions (± 500 kb) of the three sets per cell-
577 type in three cell-types, MGSS, MGSV, and MGSBT (nine total sets), for enrichment of BMI,
578 abdominal obesity (using WHRadjBMI as a proxy), and type 2 diabetes (T2D) GWAS signals

579 using GWAS summary statistics and the MAGENTA tool (see Methods). We observed
580 significant enrichments (FDR<0.05) in the ASPC MGSBT for BMI, and in the adipocyte MGSS
581 for T2D and WHRadjBMI (Table 1), while no enrichments were detected for any cell-types with
582 the MGSV sets.

583

584 Next, we assessed each marker gene set for enrichment of polygenic risk for these obesity and
585 related traits. We evaluated the predictive power of annotated polygenic risk scores (PRSs) for
586 WHRadjBMI, BMI, and T2D from the *cis* regional variants of each set in the large UK Biobank
587 (UKB) cohort. We first built PRSs for all individuals for each cell-type set and found that the
588 regional PRS constructed for the adipocyte MGSS gene set was a significant predictor
589 ($p_R^2 < 2.23 \times 10^{-308}$) of WHRadjBMI. Next, we followed up on these WHRadjBMI PRS findings
590 using permutations. Of our 10,000 permutation scores, each similarly built from SNPs residing in
591 the *cis* regions of the same number of randomly selected adipocyte expressed genes from either
592 tissue, we observed only 0.82% to have an incremental R^2 greater than or equal to that of the
593 adipocyte MGSS WHRadjBMI PRS ($R^2=1.20\%$; $p_{\text{perm}10,000}=0.0082$) (Figure 2; Supplementary
594 Table 3). Due to this observed enrichment in variance explained of WHRadjBMI, which is
595 known to be a sex-dimorphic trait^{43,55}, we also constructed these regional WHRadjBMI PRSs for
596 females and males separately. We observed the enrichment in all individuals to be driven by
597 females as the WHRadjBMI PRS constructed for the *cis* regional variants of the adipocyte
598 MGSS genes was significantly enriched ($R^2=2.12\%$, $p_{\text{perm}10,000}=0.0101$) in females, but not in
599 males (Figure 2; Supplementary Table 3). In line with previous connections with visceral adipose
600 tissue^{56,57}, we found that the variance explained for T2D was significantly enriched for the
601 adipocyte MGSV gene set (Delta AUC=1.16%, $p_{\text{perm}1,000}=0.036$). No other significant

602 enrichments in variance explained were detected for BMI or T2D in our PRS analyses, and no
603 other significant enrichments were detected for other cell-types for WHRadjBMI.

604
605 After identifying the adipocyte MGSS WHRadjBMI PRS results as significantly enriched for
606 variance explained for all individuals and females, we performed a partitioned heritability
607 analysis to further corroborate these enrichments. We observed that the heritability (h^2) of
608 WHRadjBMI from the SNPs in the *cis* regions of the adipocyte MGSS set was significantly
609 enriched in all individuals (h^2 enrichment=2.21, $p=0.00150$) and in females (h^2 enrichment=2.47,
610 $p=1.54 \times 10^{-4}$), in line with the regional PRS analysis.

611
612 Taken together, the GWAS and PRS enrichments and significant heritability enrichment results
613 highlight the adipocyte MGSS gene set as particularly important for the polygenic risk of
614 abdominal obesity.

615

616 **Identification of *SREBF1* as the key SAT-enriched adipocyte marker gene**

617 After identifying WHRadjBMI PRS enrichments in the adipocyte MGSS set, we explored the
618 functional differences of the SAT and VAT gene sets. For each major cell-type, we tested for
619 overrepresentation of genes in Gene Ontology (GO) categories using all three sets, MGSS,
620 MGSV, and MGSBT (Supplementary Tables 4-10). There were no significant functional
621 pathways for the macrophage MGSS and MGSBT sets. Among the adipocyte MGSV and
622 MGSBT gene sets, we detected 170 and 9 significant pathways, respectively ($FDR < 0.05$).

623 Among the pathways of the adipocyte MGSV gene set, 103 (61%) and 98 (58%) pathways
624 included the well-known insulin metabolism genes, *INSR* and *IRS2*, respectively. However, the

625 strongest adipose tissue function-related pathway enrichments were observed in the adipocyte
626 MGSS set (FDR<0.05), including regulation of fatty acid metabolic process, positive regulation
627 of triglyceride metabolic process, and neutral lipid metabolic process amongst other breakdown-
628 of-molecule centered processes (Supplementary Table 4).

629

630 In more detail, we found 23 significant functional pathways (FDR<0.05) for the adipocyte
631 MGSS set (Figure 3a; Supplementary Table 4). Notably, we observed a strong presence of the
632 master transcription factor (TF) of adipogenesis and fatty acid biosynthesis, *SREBF1*¹⁴, in these
633 MGSS pathways. Of the 23 enriched functional pathways for adipocyte MGSSs (FDR< 0.05), 20
634 (87%) included *SREBF1*, making it the most prevalent pathway gene, and thus supporting its
635 importance in the SAT adipocyte function. Consistent with the known role of *SREBF1* as an
636 adipose master TF^{14,58,59}, we also observed that 8 of the most prevalent pathway genes (genes
637 present in 8 or more pathways) in the adipocyte MGSS gene set are predicted transcription
638 targets of *SREBF1* that have also previously been linked to obesity, including *LEP*⁶⁰ and *FASN*⁶¹
639 (Figure 3b).

640

641 Figure 3c shows how this key MGSS TF, *SREBF1* exhibits a substantially higher adipocyte-
642 enriched expression level in SAT than VAT. We confirmed the adipocyte unique marker gene
643 status of *SREBF1* in SAT snRNA-seq in the independent RYSA cohort (n=68) (average log₂ fold
644 change=0.473, p_{adj}<2.23×10⁻³⁰⁸), thus replicating its role as a significant SAT specific marker.
645 Additionally, we replicated the lack of preferential expression of *SREBF1* in VAT adipocytes, in
646 an independent VAT snRNA-seq data from another cohort³⁴ comprising obese individuals

647 (BMI>30) of European descent (n=5), which, similarly to the KOBS VAT samples, showed low,
648 diffuse expression of *SREBF1* in all VAT cell-types (Supplementary Figure 2).

649

650 **Identification of temporally co-expressed adipocyte MGSS pathway genes during human** 651 **adipogenesis**

652 To link these functionally enriched MGSS genes to adipose tissue development and
653 differentiation, we examined the temporal expression of the key pathway genes within the
654 adipocyte MGSS set during human primary SAT preadipocyte differentiation (i.e.,
655 adipogenesis). We first identified 43 MGSS genes that contributed to more than one significantly
656 (FDR<0.05) overrepresented pathway (Supplementary Table 4) and then found that the 42 of the
657 43 genes, expressed during SAT adipogenesis, were all longitudinally differentially expressed
658 (DE) (FDR<0.05) during differentiation (Figure 3d). To link together genes with similar
659 temporal transcription patterns, we clustered these longitudinally expressed genes using DPGP⁵¹
660 into 8 groups of temporally co-expressed genes (Figure 3d, Supplementary Table 11). Of note,
661 we observed *SREBF1* to cluster with two previously described obesity genes, *LEP*⁶⁰ and *FASN*⁶¹
662 (Figure 3d), further supporting the coordinated role of *SREBF1* as a master TF with other key
663 adipocyte marker genes.

664

665 **Longitudinally differentially accessible peaks, co-accessible in the *SREBF1* region during** 666 **adipogenesis, harbor abdominal obesity GWAS variants**

667 To elucidate the genetic regulatory role of *SREBF1* in abdominal obesity, we first searched for
668 open chromatin peaks with similar temporal accessibility patterns in the *cis* region of *SREBF1*
669 during human SAT adipogenesis (Figure 4a). We detected 129 peaks in the *cis* region (\pm 500 kb)

670 of *SREBF1* and found 120 (93%) to be longitudinally DA over the 14-day preadipocyte
671 differentiation data (FDR<0.05), which we then clustered into 10 groups using DPGP⁵¹
672 (Supplementary Table 12). The clusters with peaks remaining after thresholding at a cluster
673 assignment probability>0.9 are shown in Supplementary Figure 3. We focused on cluster 4,
674 which contains 5 peaks with similar trajectories over the 14-day differentiation (Figure 4b).
675
676 To determine whether these five co-accessible peaks from cluster 4 in the *SREBF1* region
677 (Figure 4b) are involved in genetic risk of abdominal obesity, we next investigated them for
678 overlaps with WHRadjBMI GWAS variants. Using the large, previously published GWAS
679 summary statistics for WHRadjBMI from GIANT-UKB⁵², we identified 7 GWAS SNPs within
680 these 5 peaks (Table 2). Of the 7 SNPs, rs4924755, rs7224725, and rs9944423 were significant
681 ($p<5\times 10^{-8}$) in all individuals, driven by females (also significant in only females); rs35104205
682 was significant in all, females, and males; and rs12948060, rs4646347, and rs4646346 were
683 significant only in males, reflecting the well-known sex effects of the WHRadjBMI trait (Table
684 2). Furthermore, rs4924755, rs7224725, rs9944423, and rs35104205 are also significant GWAS
685 SNPs ($p<5\times 10^{-8}$) for the serum total triglycerides in all individuals from the European ancestry
686 GLGC lipid GWAS⁶².
687
688 We observed tight LD patterns ($R^2>99\%$) among three of the 7 SNPs, rs12948060, rs4646347,
689 and rs4646346, and separately among two SNPs rs7224725 and rs9944423, indicating 4 separate
690 regional WHRadjBMI signals (Figure 4c). These results show that the 5 co-accessible peaks in
691 the *SREBF1* region contribute to the genetic risk of abdominal obesity.
692

693 **Risk allele status for the abdominal obesity GWAS SNPs in the *SREBF1* cis region affects**
694 **SAT adipocyte expression of *SREBF1* and more than hundred SAT adipocyte marker**
695 **genes**

696 We hypothesized that these seven abdominal obesity GWAS variants, which reside in the *cis*
697 regulatory region of *SREBF1*, may influence the downstream expression of important adipocyte
698 genes in *trans*. To address this hypothesis, we investigated whether the risk allele status of the
699 seven WHRadjBMI GWAS SNPs in the *SREBF1* cis region impacts SAT adipocyte expression
700 of *SREBF1* and downstream, the adipocyte expression of other adipocyte MGSSs, using
701 independent SAT snRNA-seq data from another European bariatric surgery cohort, RYSA
702 (n=68) (see Methods). We identified *SREBF1* and 146 other adipocyte MGSS genes, for which
703 the adipocyte expression is significantly affected by the risk allele carrier status of one or more
704 of these seven WHRadjBMI GWAS variants in *trans* (see Methods) (Supplementary Table 13).
705 Due to the tight LD ($R^2 > 99\%$) among rs12948060, rs4646347, and rs4646346, as well as among
706 SNPs rs7224725 and rs9944423 (Figure 4c), their results are identical.

707
708 In more detail, we observed that the SAT adipocyte expression of *SREBF1* was significantly
709 impacted by each of the seven WHRadjBMI GWAS variants, being higher expressed in the risk
710 allele carriers of rs12948060, rs35104205, rs4646347, and rs4646346, and lower expressed in the
711 risk allele carriers of rs4924755, rs7224725, and rs9944423. The three SNPs in tight LD
712 (rs12948060, rs4646347, and rs4646346) had the largest number of genes (n=115 genes) with
713 significantly higher expression in the risk allele carriers (Supplementary Table 13), while the
714 SNPs rs7224725 and rs9944423 in LD ($R^2 > 99$) had the fewest (n=23 genes) (Supplementary
715 Table 13). We found that the variant rs4924755 impacted the largest number of genes with lower

716 expression in the risk-allele carriers (n=48 genes), including multiple functionally important
717 adipose genes, e.g., *FASN*, *AGPAT2*, *DGATI*, in line with the downregulation of *SREBF1* in
718 these carriers (Supplementary Table 13). The risk allele carrier status of this variant rs4924755
719 also associated with upregulation of numerous key adipose genes, such as *PLINI*, *PLIN4*, and
720 *LIPE* (Supplementary Table 13). We show the functional pathway enrichments of the gene sets
721 affected by the risk allele carrier status in Supplementary Tables 14-16.

722

723 We also built module scores in the independent RYSA cohort using the SAT adipocyte
724 expression of the up/down regulated *trans* genes by the risk allele status of the of the *SREBF1*
725 abdominal obesity GWAS SNPs (Figure 5a-b, Supplementary Figure 4). These average
726 expression results of the *trans* genes further demonstrate the significant, wide-spread *trans*
727 effects of the *SREBF1* abdominal obesity GWAS SNPs on SAT adipocyte expression. Taken
728 together, our results suggest that the WHRadjBMI GWAS SNPs in the *cis* region of *SREBF1*
729 affect SAT adipocyte expression of the major adipose tissue TF, *SREBF1*, and downstream of
730 that, the adipocyte expression of 146 genes, comprising 70% of all adipocyte MGSS genes and
731 including multiple key adipocyte MGSS genes.

732

733 **Adipocyte open chromatin variants in *cis* regions of the *trans* gene sets are enriched for**
734 **variance explained in WHRadjBMI and their PRSs differ by the risk allele carrier status of**
735 **the *SREBF1* abdominal obesity GWAS SNPs**

736 We hypothesized that the *trans* gene sets we identified had downstream effects on the polygenic
737 risk of abdominal obesity by the risk allele carrier status of the *SREBF1* abdominal obesity
738 GWAS SNPs. Accordingly, we first examined the genetic risk contributions from the *trans* genes

739 sets by constructing their regional PRSs for WHRadjBMI in UKB from the SNPs that fell in
740 adipocyte open chromatin peaks in the *cis* regions of each *trans* gene set (see Methods). We
741 found, through 10,000 permutations, that 12 out of the 21 PRSs which were built from variants
742 from upregulated *trans* gene sets were significantly enriched ($p_{\text{perm}10,000} < 0.05$) for incremental
743 variance explained in abdominal obesity (Figure 5c, Supplementary Table 17), as were 6 out of
744 the 10 PRSs built from variants from downregulated *trans* gene sets (Figure 5c, Supplementary
745 Table 18), indicating that the regulatory regions of these *trans* regulated genes are important for
746 abdominal obesity.

747
748 Next, we classified the UKB individuals as the carriers and non-carriers of the seven *SREBF1*
749 abdominal obesity GWAS risk alleles in the same way as in the RYSA adipocyte expression
750 analysis and then compared the WHRadjBMI PRSs of the *trans* gene sets between the carriers
751 and non-carriers in UKB to further assess the *trans* regulatory nature of the carrier status. We
752 found that the *SREBF1 cis* regional variants exhibit significant differences in the magnitude of
753 the regional WHRadjBMI PRSs of 10 out of the 21 upregulated *trans* gene sets between the
754 carriers and non-carriers of the corresponding *SREBF1* abdominal obesity GWAS SNP risk
755 allele (Wilcoxon $\text{padj} < 0.05$) (Supplementary Table 17), thus independently confirming the
756 observed *trans* effects in RYSA adipocytes at the population level in UKB. Similarly, we found
757 that 4 out of 10 downregulated *trans* gene sets also show significant PRS differences (Wilcoxon
758 $\text{padj} < 0.05$) between the carriers and non-carriers (Supplementary Table 18). Figure 5d shows
759 these significant differences between the regional WHRadjBMI PRSs of the *trans* genes by the
760 risk allele carrier status of one of the 7 *SREBF1* WHRadjBMI GWAS SNPs, rs4924755, and
761 Supplementary Figure 5 illustrates similar significant WHRadjBMI PRS differences with several

762 of the other SNPs. We also observed sex-specific differences in these PRS results (Figure 5c-d,
763 Supplementary Tables 17-18), in line with the well-known sex differences in abdominal obesity.
764 Overall, our results discover *SREBF1* for SAT adipocyte function and genetic risk of abdominal
765 obesity via variant-specific *trans* effects on numerous adipocyte *trans* genes.

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785 **Discussion**

786 Despite prevailing cellular heterogeneity within and between the two major human fat depots,
787 SAT and VAT, the underlying genes, functional pathways, and epigenetic and genetic factors
788 explaining these differences have remained largely elusive at the cell-type resolution^{63–65}.
789 Previous studies have reliably connected SAT and VAT to obesity and related cardiometabolic
790 metabolic diseases (CMDs)^{2,4,5,54}, but the distinct contributions of each fat tissue and their cell-
791 types to disease predisposition are less well understood. Here, we integrated human single-cell
792 level RNA data to comprehensively compare SAT and VAT at the transcriptomic level. By
793 deriving tissue- and cell-type-specific marker gene sets (MGSS, MGSV, and MGSBT) for each
794 of the three major adipose cell-types, we establish which unique cell-type marker genes are
795 shared and which ones are specific to adipocytes, ASPCs, and macrophages in SAT versus VAT
796 and how these genes contribute to the key cell-type functions and genetic risks to CMDs. Upon
797 assessing the GWAS associations, partitioned polygenic risk scores, and heritability estimates in
798 these cell-type marker gene sets, we highlighted the importance of the adipocyte marker genes
799 unique to the SAT depot for genetic predisposition to abdominal obesity, led by the major
800 adipose TF gene, *SREBF1*, observed in 87% of the functional pathways unique to the SAT
801 adipocyte marker genes. We also discover regional, longitudinally co-accessible peaks across
802 SAT adipogenesis at this *SREBF1* locus, which harbor seven GWAS variants associated with
803 WHRadjBMI, a well-established abdominal obesity proxy¹¹. Next, we show that the risk allele
804 carrier status of these seven WHRadjBMI GWAS variants affects SAT adipocyte expression of
805 *SREBF1* and 146 other functionally enriched SAT adipocyte marker genes (i.e., 70% of all SAT
806 adipocyte marker genes) in the large independent SAT snRNA-seq data set from the RYSA
807 cohort, identifying profound cell-type level downstream effects of this adipose major TF in

808 *trans*. Lastly, we confirm this result independently in the UK Biobank by demonstrating that the
809 partitioned abdominal obesity PRSs of the adipocyte *trans* gene sets differ by the risk allele
810 carrier status of the *SREBF1* abdominal obesity GWAS variants. Taken together, our study
811 discovers abdominal obesity GWAS variants in the *cis* region of *SREBF1* that act in *trans* as
812 drivers of downstream adipocyte gene expression of more than a hundred of genes.

813

814 Previous studies have shown that excess VAT leads to increased risk for MASLD, insulin
815 resistance, and coronary artery disease^{56,57} and that excess SAT is correlated with an increase in
816 oxidative stress and inflammation⁶⁶, but the cell-type and gene level mechanisms underlying
817 these different depot-specific contributions to CMD predispositions are not well understood. In
818 our study, by leveraging the snRNA-seq data from the same KOBS participants' SAT and VAT
819 biopsies, we characterize gene expression without inter-individual bias and separate cell-type
820 marker genes into shared and tissue-specific gene sets. While previous studies have similarly
821 discerned both partial differences in the cell-type identities and functionalities of shared cell-
822 types⁶⁷⁻⁷⁰, our study further examines these tissue-shared and specific profiles in the context of
823 the CMD risks. Through constructing partitioned polygenic risk scores which isolate the
824 polygenic risk contributions from the regional variants in the genes at the center of these tissue
825 profiles, we discern enrichment for the abdominal obesity PRS from the adipocyte SAT-specific
826 marker genes, further supported by our WHRadjBMI heritability analysis of the adipocyte
827 MGSS gene set by LD score regression. We additionally confirm previously known connections
828 of VAT to T2D^{56,57} through identifying enrichment for T2D PRS from the adipocyte VAT-
829 specific marker genes. Overall, our genetic results suggest that the genetically regulated
830 transcriptional differences between the two human fat depots link to substantial distinctions

831 between the tissue- and cell-type level contributions to CMDs. When investigating the role of
832 sex as a biological factors, we also found that the regional PRSs constructed from the local
833 variants of the adipocyte SAT-specific marker genes are highly enriched predictors of
834 WHRadjBMI in all individuals and females, in line with the previously established heritability
835 enrichments of WHRadjBMI in SAT, sex-dimorphisms of WHRadjBMI, and the causality
836 estimates of WHRadjBMI for MASLD^{71,72}.

837
838 We further elucidate patterns of tissue and cell-type specificity among the two fat depots through
839 evaluating the functional enrichments among the SAT and VAT marker gene sets. In line with
840 previously identified cellular heterogeneity between the two tissues^{34,70}, we observe that the
841 adipocyte SAT-specific marker genes are enriched for genes involved in the metabolism of fatty
842 acids, triglycerides, and glucose, while the adipocyte marker genes shared across the depots, or
843 specific to VAT exhibited enrichment in molecular movement and lipid localization. These
844 results are supported by previous studies that found that VAT is important for a flux of fatty acid
845 buildup⁷³, which suggests that while VAT would be important for the long-term fat storage-
846 oriented properties of adipose tissue, SAT may be more influential for the metabolic activities,
847 such as rapid-expansion of fat molecules, and flexible breakdown of fat-related molecules. In
848 particular, we identified *SREBF1* as the key to the adipocyte MGSS functional pathways, found
849 in 87% of the SAT-specific significant functional pathways. *SREBF1* is the fatty acid synthesis
850 master TF and a key regulator of transcriptional control for adipogenesis^{14,15}. It also regulates the
851 transcription of several obesity-involved gene pathways¹⁵. In our study, we observed a distinct
852 upregulation of *SREBF1* adipocyte expression in SAT, compared to its sparse and diffuse
853 expression across all cell-types in VAT, a pattern that we replicated in independent SAT and

854 VAT cohorts³⁴. Consistent with our genetic assessments, these patterns suggest that the
855 contributions to abdominal obesity may be more pronounced in SAT adipocytes than in the VAT
856 counterparts. Although other studies have shown low diffuse expression levels of *SREBF1* across
857 multiple cell-types in VAT⁵⁸, our study discovers *SREBF1* as a unique adipocyte-specific marker
858 gene in SAT involved in numerous functional SAT pathways not enriched among the VAT
859 adipocyte marker genes, which may explain functional differences between SAT and VAT given
860 the well-established regulatory role of this master TF. Furthermore, we present differences in
861 SAT adipocyte gene expression of the key adipocyte marker genes between the carriers and non-
862 carriers of the abdominal obesity GWAS variants in the *cis* region of *SREBF1*, supporting the
863 evidence of *SREBF1* as a master transcription factor with more than a hundred important target
864 genes in SAT adipocytes. Taken together, we find that differences in cell-type-specific gene
865 expression between SAT and VAT link to differences in SAT and VAT function and identify
866 one such gene, *SREBF1* that is present in most SAT adipocyte-specific pathways and absent in
867 VAT adipocyte-specific pathways.

868
869 When investigating the genetic contribution of the *SREBF1* region to abdominal obesity, we
870 found that co-accessible adipocyte ATAC-seq peaks in the *cis* region of *SREBF1* harbor multiple
871 genome-wide significant WHRadjBMI GWAS variants, including variants with sex-specific
872 associations, thus linking to the well-established sex-dimorphism of the abdominal obesity^{11,43,55}.
873 We also discovered using SAT adipocyte expression data from the large independent RYSA
874 cohort that these WHRadjBMI GWAS risk variants are associated with expression of 146
875 adipocyte marker genes specific to SAT, including *SREBF1*. These adipocyte marker genes,
876 impacted by the risk allele carrier status, are also functionally enriched for important adipocyte

877 functions. Next, we further confirm these single cell-level *trans* effects by building partitioned
878 abdominal obesity PRSs of these *trans* gene sets in the UK Biobank data, which shows that their
879 partitioned abdominal obesity PRSs differ by the risk allele carrier status of the *SREBF1*
880 abdominal obesity GWAS variants, thus highlighting their downstream *trans* effects of the
881 *SREBF1* variants also at the genomic level. Overall, our results identify *trans* effects on SAT
882 adipocyte gene expression by the WHRadjBMI risk variants in the *SREBF1* region using several
883 different data modalities and cohorts. Given the known important TF functional of *SREBF1*, our
884 results support the notion that these WHRadjBMI GWAS risk variants in the regulatory region of
885 *SREBF1* have downstream effects in *trans* on transcriptional regulation of numerous central
886 obesity -related genes. More broadly, our study also provides an integrative genomics approach,
887 leveraging single cell omics and biobank data, that can be generalized to other TFs to accelerate
888 the currently slow discovery of *trans* effects of TF GWAS variants.

889

890 We acknowledge several limitations in our study. First, while our KOBS snRNA-seq data pass a
891 rigorous QC, the total number of SAT and VAT nuclei in the KOBS cohort are relatively small.
892 However, the publicly available VAT snRNA-seq data are currently very sparse, and using our
893 dual tissue study design with both SAT and VAT biopsies from the same Finnish individuals
894 with obesity, we at least partially circumvent a well known factor in snRNA-seq data analysis,
895 i.e., the interindividual cellular heterogeneity^{34,49} that may affect the assessment of the cell-type
896 marker genes. Furthermore, we conducted the risk allele carrier status –based analyses in the
897 large independent RYSA snRNA-seq data set and confirmed the key SAT and VAT results of
898 the *SREBF1* cell-type level expression in the RYSA cohort and previous adipose ATLAS by
899 Emont and coworkers³⁴. Second, as we assessed adipogenesis data only from the SAT depot due

900 to the well-known practical and technical challenges to obtain viable human VAT primary
901 preadipocytes - which is also reflected by the current lack of longitudinal human VAT
902 adipogenesis RNA-seq data in the public data repositories - it would be important to also explore
903 adipogenesis differentiating human VAT primary preadipocytes in future studies. Third, the
904 cohorts and analyses of this study comprise Europeans from Finland and the UK. Extrapolations
905 to diverse ethnicities are warranted to further investigate these findings. Lastly, the SAT and
906 VAT biopsies in the current study are from individuals with obesity and thus, studies in
907 individuals with normal weight and overweight may provide important additional information
908 regarding the impact of the obese condition on these results.

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923 **Figure Legends**

924 **Figure 1**

925 **Adipose single nucleus RNA-sequence data from the KOBS participants' subcutaneous**
926 **adipose tissue (SAT) and visceral adipose tissue (VAT) identify distinct sets of tissue-**
927 **specific and shared cell-type marker genes.** (a) The study design visualized through cohort
928 usage. The data from the individuals in the KOBS cohort were used to identify cell-type marker
929 gene sets, while the data from the individuals in the RYSA cohort were used to identify *trans*
930 gene sets by the carrier status of the *SREBF1* risk alleles. Lastly, all polygenic risk scores were
931 built using individuals from the UK Biobank. (b-c) The integrated SAT and VAT single nucleus
932 RNA-seq data (n=6,732 nuclei) from 7 KOBS participants are visualized in a Uniform Manifold
933 Approximation and Projection (UMAP) and colored by (b) fat depot of origin and (c) cluster
934 cell-type identity, while mapping each cluster to one of the 16 identified cell-types. ASPC
935 indicates adipose stem and progenitor cells; B, B cells; LEC, lymphatic endothelial cells; NK,
936 natural killer cells; SMC, smooth muscle cells; and T, T cells. (d) A volcano plot depicts
937 differential expression (DE) of the unique adipocyte marker genes by tissue. Genes are grouped
938 into marker genes specific to SAT (MGSS), specific to VAT (MGSV), and shared between the
939 SAT and VAT tissues (MGSBT) (see Methods), and then colored by these groups.

940

941 **Figure 2**

942 **Regional polygenic risk scores (PRSs) constructed from the *cis* regional variants of the**
943 **adipocyte MGSS gene sets show enrichment in variance explained for abdominal obesity in**
944 **all individuals and females of the UK Biobank.** Lollipop plots visualize the predictive
945 performance of each regional PRS relative to the 10,000 PRSs built using the same number of

946 randomly selected adipocyte-expressed genes. Each horizontal lollipop represents a separate
947 regional PRS, broken into three categories on the left (all individuals, females, and males). Dot
948 size corresponds to the variance explained, R^2 , of each PRS. The vertical dotted line represents
949 the cutoff for significance ($p_{\text{perm}10,000} < 0.05$).

950

951 **Figure 3**

952 **Functional pathway enrichment analyses of cell- and tissue-type level expression profiles**
953 **reveal distinctive differences in SAT and VAT pathways and highlight the adipose master**
954 **transcription factor *SREBF1* as the central pathway gene present in 87% of the adipocyte**
955 **MGSS pathways.** (a) The top 10 most significant ($\text{FDR} < 0.05$) functional pathways for
956 adipocyte MGSS and MGSV are shown side by side, colored by adipocyte tissue-specific set. P-
957 values for each pathway are shown on the x-axis, and each pathway is subsequently ranked by
958 decreasing p-value. The point size of each dot corresponds to the enrichment ratio of the
959 pathway. (b) Circos plots visualize the pathway memberships of the adipocyte MGSS genes that
960 appear in ≥ 8 adipocyte MGSS pathways and connect the genes to their respective pathways.
961 Genes denoted with an asterisk are predicted target genes of *SREBF1*. Each gene is colored by
962 the number of pathways it belongs to. We highlight *SREBF1*, an adipose tissue master TF and a
963 key pathway gene that is present in 20 out of 23 pathways enriched in adipocyte MGSSs. (c) The
964 cell-type level expression of *SREBF1* across both fat depots is shown on the UMAP space,
965 separately for SAT and VAT, and colored by normalized gene expression counts. d) The scaled
966 expression counts over a 14-day adipocyte differentiation experiment of the longitudinally
967 differentially expressed (DE) adipocyte MGSS genes with memberships in multiple enriched
968 pathways are plotted and grouped by their longitudinal expression trajectory clusters.

969

970 **Figure 4**

971 **Longitudinal trajectory analysis of open chromatin reveals co-accessible peaks in the *cis***

972 **region of *SREBF1* that harbor WHRadjBMI variants.** (a) A regional schematic overview

973 shows the proximity to *SREBF1* of 5 co-accessible peaks that exhibit very similar open

974 chromatin trajectory patterns. The peaks collectively harbor WHRadjGWAS variants, viewable

975 through zoomed in loci of the chromosome. (b) The temporal accessibility patterns of the 5 peaks

976 in the *SREBF1* are plotted across the 14-day, 6 time-point SAT preadipocyte differentiation

977 experiment. (c) The pairwise linkage disequilibrium (LD) (R^2) in the UK Biobank (n=9,981)

978 between the 7 WHRadjBMI GWAS SNPs residing within the co-accessible adipocyte peaks in

979 the *SREBF1 cis* region is shown as a HaploView plot, colored by R^2 .

980

981 **Figure 5**

982 ***Trans* effects of *SREBF1* abdominal obesity GWAS SNPs established using single cell level**

983 **expression data and biobank investigation.** (a) *Trans* effects of abdominal obesity GWAS

984 SNPs in the *SREBF1* region on SAT adipocyte expression of the adipocyte MGSS genes in an

985 allele-specific way is shown using module scores, constructed in the RYSA cohort (n=68) using

986 the average SAT adipocyte expression of the upregulated *trans* genes by the risk allele status of

987 the *SREBF1* GWAS SNPs. For the module scores of the downregulated *trans* genes, see

988 Supplementary Figure 4. The plots represent the module scores calculated for the upregulated

989 *trans* genes by each SNP (or by a SNP representing a tight LD block, see Figure 4c). Thus, the

990 module scores for the LD block of rs12948060, rs4646347, and rs4646346 and the LD block of

991 rs7224725 and rs9944423 are shown using the data for rs12948060 and rs7224725. Each point

992 represents a cell and its average gene expression of the *trans* genes of interest. (b) The
993 differences between the carriers and non-carriers are also visualized through a two-sided
994 Wilcoxon test and boxplot. (c) The *trans* gene sets are enriched for variance explained in
995 abdominal obesity. Lollipop plots show the regional PRS results for each *trans* gene set
996 (constructed in all individuals and females). Entries missing a lollipop did not either have enough
997 SNPs to accurately build a PRS (<5 SNPs) or significantly predict the variance in WHRadjBMI
998 ($p_{R^2} > 0.05$) after the regional PRS construction. (c) Differences in the magnitude of the regional
999 PRSs between the carriers and non-carriers of the abdominal obesity risk allele for rs4924755
1000 visualized through boxplots. Significance is calculated using a two-sided Wilcoxon test. Plots for
1001 the regional WHRadjBMI PRSs of the *trans* genes calculated in females and all individuals in
1002 UKB are displayed.

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017 **Author contributions**

1018 M. G. S. and P. P. designed the study. M. G. S., A. K., S. H. T. L., K. Z. G., and S. S. D.
1019 performed computational analysis and relevant literature comparisons. M. G. S., A. K., S. H. T.
1020 L., M. A., and P. P. developed the analytical and statistical approaches. K. M. G. and P. P.
1021 generated the ATAC-seq data. U. T. A., S. H. T. L., S. R., K. H. P., M. U. K., and P. P. generated
1022 the RNA-seq data. M. A., D. K., and P. P. generated the genotype data. D. K., V. M., H. P., S.
1023 H., U. S., T. S., A. J., K. H. P., J. P., and M. U. K. collected the cohort materials. M. G. S., A. K.,
1024 S. H. T. L., and P. P. wrote the manuscript, and all authors read, reviewed, and/or edited the
1025 manuscript.

1026

1027 **Declaration of interests**

1028 The authors declare no competing interests.

1029

1030 **Acknowledgments**

1031 We would like to thank the participants of the KOBS, RYSA, and Tilkka cohorts, and the UK
1032 Biobank. This study was supported by NIH grants R01HL170604 (PP) and R01DK132775 (PP),
1033 the Academy of Finland (272376, 266286, 314383, 335443, KHP; 314457 AJ: 338417 SH; and
1034 333021, 335973, MUK), Finnish Medical Foundation (KHP, AJ), Finnish Diabetes Research
1035 Foundation (SH, KHP), Orion Foundation (SH), Novo Nordisk Foundation (NNF10OC1013354,
1036 NNF17OC0027232, NNF20OC0060547, KHP), Paulo Foundation (SH, KHP), Gyllenberg
1037 Foundation (KHP), Sigrid Juselius Foundation (KHP, MUK), Paavo Nurmi Foundation (SH),
1038 Helsinki University Hospital Research Funds (SH, KHP, AJ) and the University of Helsinki
1039 (KHP). This research was partly supported by the European Research Council (ERC) under the

1040 European Union’s Horizon 2020 research and innovation program (Grant 802825 to MUK), and
1041 the Finnish Foundation for Cardiovascular Research (MUK). We would like to acknowledge
1042 Single Cell Genomics Core and Biocenter Finland for infrastructure support. This work uses data
1043 provided by patients and collected by the NHS as part of their care and support. This research
1044 was conducted using the UK Biobank Resource under application number 33934.

1045

1046 **Supplemental information**

1047 Document S1. Supplementary Table 17, Supplementary Table 18, Supplementary Figure 2,

1048 Supplementary Figure 3, Supplementary Figure 4, Supplementary Figure 5

1049 Supplementary Table 1. Excel file containing additional data, related to Figure 1

1050 Supplementary Table 2. Excel file containing additional data, related to Figure 1

1051 Supplementary Table 3. Excel file containing additional data, related to Figure 2

1052 Supplementary Table 4. Excel file containing additional data, related to Figure 3

1053 Supplementary Table 5. Excel file containing additional data, related to Figure 3

1054 Supplementary Table 6. Excel file containing additional data, related to Figure 3

1055 Supplementary Table 7. Excel file containing additional data, related to Figure 3

1056 Supplementary Table 8. Excel file containing additional data, related to Figure 3

1057 Supplementary Table 9. Excel file containing additional data, related to Figure 3

1058 Supplementary Table 10. Excel file containing additional data, related to Figure 3

1059 Supplementary Table 12. Excel file containing additional data, related to Figure 4

1060 Supplementary Table 13. Excel file containing additional data, related to Figure 5

1061 Supplementary Table 14. Excel file containing additional data, related to Figure 5

1062 Supplementary Table 15. Excel file containing additional data, related to Figure 5

1063 Supplementary Table 16. Excel file containing additional data, related to Figure 5

1064

1065 **Data availability statement**

1066 The data that support the findings in this manuscript are available from the UK Biobank.

1067 However, restrictions apply to the availability of these data, which were used in this study under

1068 UK Biobank Application number 33934. UK Biobank data are available for bona fide

1069 researchers through the application process: [https://www.ukbiobank.ac.uk/learn-more-about-uk-](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us)

1070 [biobank/contact-us](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us). The KOBS VAT snRNA-seq will be made available in the NIH Gene

1071 Expression Omnibus (GEO) upon acceptance, under accession number GSEXX. The KOBS

1072 SAT snRNA-seq data were made previously available in GEO, under accession number

1073 GSE269926. The RYSA SAT snRNA-seq data will be made available in GEO under accession

1074 number GSE274778. The data from the primary human preadipocyte differentiation experiment

1075 were previously made available in GEO, under accession number GSE249195 for the RNA and

1076 GSE269926 for the ATAC. The SAT and VAT snRNA-seq data described in Emont et al.³⁴ can

1077 be found in the Single Cell Portal under study number SCP1376.

1078

1079 **Code availability**

1080 No custom code was used, and all codes used for analyses in this study were unaltered from their

1081 publicly available sources, as outlined in the Methods.

1082

1083

1084

1085

1086

1087 **References**

- 1088 1. Vegiopoulos, A., Rohm, M. & Herzig, S. Adipose tissue: between the extremes. *EMBO J.* 36, 1999–
1089 2017 (2017).
- 1090 2. Merlotti, C., Ceriani, V., Morabito, A. & Pontiroli, A. E. Subcutaneous fat loss is greater than
1091 visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical
1092 review and meta-analysis. *Int. J. Obes.* 2005 41, 672–682 (2017).
- 1093 3. Pellegrinelli, V., Carobbio, S. & Vidal-Puig, A. Adipose tissue plasticity: how fat depots respond
1094 differently to pathophysiological cues. *Diabetologia* 59, 1075–1088 (2016).
- 1095 4. Bays, H. E. *et al.* Pathogenic potential of adipose tissue and metabolic consequences of adipocyte
1096 hypertrophy and increased visceral adiposity. *Expert Rev. Cardiovasc. Ther.* 6, 343–368 (2008).
- 1097 5. Gesta, S., Tseng, Y.-H. & Kahn, C. R. Developmental origin of fat: tracking obesity to its source.
1098 *Cell* 131, 242–256 (2007).
- 1099 6. Garske, K. M. *et al.* Increased body mass index is linked to systemic inflammation through altered
1100 chromatin co-accessibility in human preadipocytes. *Nat. Commun.* 14, 4214 (2023).
- 1101 7. Lee, S. H. T. *et al.* Single nucleus RNA-sequencing integrated into risk variant colocalization
1102 discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated
1103 steatotic liver disease. *EBioMedicine* 106, 105232 (2024).
- 1104 8. Pan, D. Z. *et al.* Integration of human adipocyte chromosomal interactions with adipose gene
1105 expression prioritizes obesity-related genes from GWAS. *Nat. Commun.* 9, 1512 (2018).
- 1106 9. Brotman, S. M. *et al.* Adipose tissue eQTL meta-analysis reveals the contribution of allelic
1107 heterogeneity to gene expression regulation and cardiometabolic traits. *BioRxiv Prepr. Serv. Biol.*
1108 2023.10.26.563798 (2023) doi:10.1101/2023.10.26.563798.
- 1109 10. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues.
1110 *Science* 369, 1318–1330 (2020).

- 1111 11. Pan, D. Z. *et al.* Identification of TBX15 as an adipose master trans regulator of abdominal obesity
1112 genes. *Genome Med.* 13, 123 (2021).
- 1113 12. Grundberg, E. *et al.* Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nat.*
1114 *Genet.* 44, 1084–1089 (2012).
- 1115 13. Civelek, M. *et al.* Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits. *Am.*
1116 *J. Hum. Genet.* 100, 428–443 (2017).
- 1117 14. Ayala-Sumuan, J.-T. *et al.* Srebf1a is a key regulator of transcriptional control for adipogenesis. *Sci.*
1118 *Rep.* 1, 178 (2011).
- 1119 15. Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology - divergent
1120 pathophysiology. *Nat. Rev. Endocrinol.* 13, 710–730 (2017).
- 1121 16. van der Kolk, B. W. *et al.* Differential Mitochondrial Gene Expression in Adipose Tissue Following
1122 Weight Loss Induced by Diet or Bariatric Surgery. *J. Clin. Endocrinol. Metab.* 106, 1312–1324
1123 (2021).
- 1124 17. Pihlajamäki, J. *et al.* Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after
1125 gastric banding. *Metabolism.* 59, 866–872 (2010).
- 1126 18. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562,
1127 203–209 (2018).
- 1128 19. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* 526,
1129 68–74 (2015).
- 1130 20. Heinonen, S. *et al.* Roux-en-Y versus one-anastomosis gastric bypass (RYSA study): weight loss,
1131 metabolic improvements, and nutrition at 1 year after surgery, a multicenter randomized controlled
1132 trial. *Obes. Silver Spring Md* 31, 2909–2923 (2023).
- 1133 21. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
1134 *GigaScience* 4, s13742-015-0047–8 (2015).
- 1135 22. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* 48,
1136 1279–1283 (2016).

- 1137 23. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat.*
1138 *Genet.* 48, 1443–1448 (2016).
- 1139 24. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* 48, 1284–1287
1140 (2016).
- 1141 25. GENCODE 2021 - PubMed. <https://pubmed.ncbi.nlm.nih.gov/33270111/>.
- 1142 26. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinforma. Oxf. Engl.* 29, 15–21
1143 (2013).
- 1144 27. Alvarez, M. *et al.* Enhancing droplet-based single-nucleus RNA-seq resolution using the semi-
1145 supervised machine learning classifier DIEM. *Sci. Rep.* 10, 11019 (2020).
- 1146 28. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* 184, 3573-3587.e29 (2021).
- 1147 29. Yang, S. *et al.* Decontamination of ambient RNA in single-cell RNA-seq with DecontX. *Genome*
1148 *Biol.* 21, 57 (2020).
- 1149 30. Kang, H. M. *et al.* Multiplexed droplet single-cell RNA-sequencing using natural genetic variation.
1150 *Nat. Biotechnol.* 36, 89–94 (2018).
- 1151 31. McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet Detection in Single-Cell
1152 RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst.* 8, 329-337.e4 (2019).
- 1153 32. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat.*
1154 *Methods* 16, 1289–1296 (2019).
- 1155 33. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
1156 profibrotic macrophage. *Nat. Immunol.* 20, 163–172 (2019).
- 1157 34. Emont, M. P. *et al.* A single-cell atlas of human and mouse white adipose tissue. *Nature* 603, 926–
1158 933 (2022).
- 1159 35. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat.*
1160 *Commun.* 8, 14049 (2017).
- 1161 36. Tutorial: guidelines for annotating single-cell transcriptomic maps using automated and manual
1162 methods | Nature Protocols. <https://www.nature.com/articles/s41596-021-00534-0>.

- 1163 37. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis toolkit
1164 with revamped UIs and APIs. *Nucleic Acids Res.* 47, W199–W205 (2019).
- 1165 38. Segrè, A. V. *et al.* Common inherited variation in mitochondrial genes is not enriched for
1166 associations with type 2 diabetes or related glycemetic traits. *PLoS Genet.* 6, e1001058 (2010).
- 1167 39. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature* 627,
1168 347–357 (2024).
- 1169 40. Collister, J. A., Liu, X. & Clifton, L. Calculating Polygenic Risk Scores (PRS) in UK Biobank: A
1170 Practical Guide for Epidemiologists. *Front. Genet.* 13, 818574 (2022).
- 1171 41. Sw, C., Ts, M. & Pf, O. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.*
1172 15, (2020).
- 1173 42. Fried, S. K., Lee, M.-J. & Karastergiou, K. Shaping fat distribution: new insights into the molecular
1174 determinants of depot- and sex-dependent adipose biology. *Obes. Silver Spring Md* 23, 1345–1352
1175 (2015).
- 1176 43. Schorr, M. *et al.* Sex differences in body composition and association with cardiometabolic risk. *Biol.*
1177 *Sex Differ.* 9, 28 (2018).
- 1178 44. Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores via penalized
1179 regression on summary statistics. *Genet. Epidemiol.* 41, 469–480 (2017).
- 1180 45. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-density
1181 imputation and islet-specific epigenome maps. *Nat. Genet.* 50, 1505–1513 (2018).
- 1182 46. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat. Genet.* 54,
1183 573–580 (2022).
- 1184 47. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in
1185 genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).
- 1186 48. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
1187 association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).

- 1188 49. Kar, A. *et al.* Age-dependent genes in adipose stem and precursor cells affect regulation of fat cell
1189 differentiation and link aging to obesity via cellular and genetic interactions. *Genome Med.* 16, 19
1190 (2024).
- 1191 50. Fischer, D. S., Theis, F. J. & Yosef, N. Impulse model-based differential expression analysis of time
1192 course sequencing data. *Nucleic Acids Res.* 46, e119 (2018).
- 1193 51. McDowell, I. C. *et al.* Clustering gene expression time series data using an infinite Gaussian process
1194 mixture model. *PLoS Comput. Biol.* 14, e1005896 (2018).
- 1195 52. Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in
1196 694 649 individuals of European ancestry. *Hum. Mol. Genet.* 28, 166–174 (2019).
- 1197 53. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-
1198 seq data with DESeq2. *Genome Biol.* 15, 550 (2014).
- 1199 54. Emdin, C. A. *et al.* Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2
1200 Diabetes, and Coronary Heart Disease. *JAMA* 317, 626–634 (2017).
- 1201 55. Rask-Andersen, M., Karlsson, T., Ek, W. E. & Johansson, Å. Genome-wide association study of
1202 body fat distribution identifies adiposity loci and sex-specific genetic effects. *Nat. Commun.* 10, 339
1203 (2019).
- 1204 56. Vecchié, A. *et al.* Obesity phenotypes and their paradoxical association with cardiovascular diseases.
1205 *Eur. J. Intern. Med.* 48, 6–17 (2018).
- 1206 57. González, N., Moreno-Villegas, Z., González-Bris, A., Egido, J. & Lorenzo, Ó. Regulation of
1207 visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and
1208 diabetes. *Cardiovasc. Diabetol.* 16, 44 (2017).
- 1209 58. Li, L.-Y. *et al.* Interplay and cooperation between SREBF1 and master transcription factors regulate
1210 lipid metabolism and tumor-promoting pathways in squamous cancer. *Nat. Commun.* 12, 4362
1211 (2021).
- 1212 59. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of
1213 cholesterol and fatty acid synthesis in the liver. *J. Clin. Invest.* 109, 1125–1131 (2002).

- 1214 60. Obradovic, M. *et al.* Leptin and Obesity: Role and Clinical Implication. *Front. Endocrinol.* 12,
1215 585887 (2021).
- 1216 61. Matsukawa, T. *et al.* Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease
1217 and diabetes in mouse obesity models. *JCI Insight* 8, e161282 (2023).
- 1218 62. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of lipids.
1219 *Nature* 600, 675–679 (2021).
- 1220 63. Fox, C. S. *et al.* Abdominal visceral and subcutaneous adipose tissue compartments: association with
1221 metabolic risk factors in the Framingham Heart Study. *Circulation* 116, 39–48 (2007).
- 1222 64. Gealekman, O. *et al.* Depot-specific differences and insufficient subcutaneous adipose tissue
1223 angiogenesis in human obesity. *Circulation* 123, 186–194 (2011).
- 1224 65. Chau, Y.-Y. *et al.* Visceral and subcutaneous fat have different origins and evidence supports a
1225 mesothelial source. *Nat. Cell Biol.* 16, 367–375 (2014).
- 1226 66. Pou, K. M. *et al.* Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to
1227 markers of inflammation and oxidative stress: the Framingham Heart Study. *Circulation* 116, 1234–
1228 1241 (2007).
- 1229 67. Norreen-Thorsen, M. *et al.* A human adipose tissue cell-type transcriptome atlas. *Cell Rep.* 40,
1230 111046 (2022).
- 1231 68. Ahn, J., Wu, H. & Lee, K. Integrative Analysis Revealing Human Adipose-Specific Genes and
1232 Consolidating Obesity Loci. *Sci. Rep.* 9, 3087 (2019).
- 1233 69. Arner, P. Differences in lipolysis between human subcutaneous and omental adipose tissues. *Ann.*
1234 *Med.* 27, 435–438 (1995).
- 1235 70. Vijay, J. *et al.* Single-cell analysis of human adipose tissue identifies depot and disease specific cell
1236 types. *Nat. Metab.* 2, 97–109 (2020).
- 1237 71. Milić, S., Lulić, D. & Štimac, D. Non-alcoholic fatty liver disease and obesity: biochemical,
1238 metabolic and clinical presentations. *World J. Gastroenterol.* 20, 9330–9337 (2014).

- 1239 72. Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Obesity and nonalcoholic fatty liver disease: From
1240 pathophysiology to therapeutics. *Metabolism*. 92, 82–97 (2019).
- 1241 73. Zacharia, A. *et al.* Distinct infrastructure of lipid networks in visceral and subcutaneous adipose
1242 tissues in overweight humans. *Am. J. Clin. Nutr.* 112, 979–990 (2020).
- 1243
- 1244

Table 1. Variants in the *cis* regions of genes in the SAT and tissue-shared adipocyte unique marker gene sets are significantly enriched for obesity and type 2 diabetes GWAS SNPs.

Gene set ^A	GWAS outcome ^B	FDR ^C
Adipocyte MGSS	T2D	4.30×10^{-3}
Adipocyte MGSS	WHRadjBMI	1.77×10^{-2}
ASPC MGSBT	BMI	2.93×10^{-2}

^A MGSS indicates the unique marker genes specific to subcutaneous adipose tissue (SAT), and MGSBT the unique marker genes shared between the two fat depots.

^B WHRadjBMI indicates waist-hip-ratio adjusted for body mass index, T2D type 2 diabetes, BMI body mass index, and GWAS genome-wide association study.

^C Significance was determined by comparing observed vs expected number of genes that passed 75% enrichment cutoff using MAGENTA³⁸.

Table 2. Open chromatin peaks co-accessible during human SAT adipogenesis in the *cis* region of *SREBF1* harbor seven genome-wide significant WHRadjBMI GWAS variants from GIANT-UKB WHRadjBMI GWAS⁵².

Variant	Effect allele ^A	Males		Females		All individuals	
		Beta ^B	p-value	Beta	p-value	Beta	p-value
rs4924755	G	0.0133	8.32×10 ⁻⁶	0.0209	2.05×10 ⁻¹⁵	0.0186	6.89×10 ⁻²¹
rs12948060	T	0.0183	1.60×10 ⁻¹¹	3.80×10 ⁻³	0.114	9.30×10 ⁻³	2.64×10 ⁻⁷
rs35104205	C	0.0199	1.75×10 ⁻¹¹	0.0149	2.45×10 ⁻⁸	0.0167	3.56×10 ⁻¹⁷
rs4646347	T	0.0199	2.81×10 ⁻¹¹	1.50×10 ⁻³	0.579	8.90×10 ⁻³	8.37×10 ⁻⁶
rs4646346	C	0.0199	2.43×10 ⁻¹¹	9.00×10 ⁻⁴	0.738	8.60×10 ⁻³	1.92×10 ⁻¹⁵
rs9944423	G	8.50×10 ⁻³	0.103	0.0394	1.38×10 ⁻¹⁶	0.0258	4.27×10 ⁻¹³

^A Trait-increasing allele indicating the allele of the variant that results in a positive effect on waist-hip-ratio adjusted for body mass index (WHRadjBMI).

^B Effect size on WHRadjBMI per copy of WHRadjBMI-increasing allele.

Table 3. Investigation of seven WHRadjBMI GWAS variants for histone modifications reveals activity in enhancer and promoter regions.

Variant	Group ^A	Chromatin states (15-state model) ^B	Chromatin states (25-state model) ^C	H3K4me1 ^D	H3K4me3 ^E	H3K27ac ^F	H3K9ac ^G
rs4924755	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	TssAFlnk	EnhA1	Enh	Pro		Pro
	Fat.Adip.Nuc	TssAFlnk	TxReg	Enh	Pro	Enh	Pro
rs12948060	Fat.Msc.Dr.Adip	TssAFlnk	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	Enh	EnhAF	Enh	-	-	Pro
	Fat.Adip.Nuc	Enh	EnhW2	Enh	Pro	Enh	Pro
rs35104205	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	TssAFlnk	EnhA1	Enh	Pro	Enh	Pro
rs4646347	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	TssAFlnk	EnhA1	Enh	Pro	Enh	Pro
rs4646346	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	TssAFlnk	EnhA1	Enh	Pro	Enh	Pro
rs7224725	Fat.Msc.Dr.Adip	TssAFlnk	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	TssAFlnk	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	Enh	PromD1	Enh	Pro	Enh	Pro
rs9944423	Fat.Msc.Dr.Adip	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	Enh	TxReg	Enh	Pro	Enh	Pro

^A Description of cell-line. Fat.Msc.Dr.Adip refers to Mesenchymal Stem Cell Derived Adipocyte Cultured Cells, Fat.Adip.Dr.Msc refers to Adipose Derived Mesenchymal Stem Cell Cultured Cells and Fat.Adip.Nuc refers to Adipose Nuclei.

^B Chromatin state from the HaploReg database which uses the 15-state core model. TssAFlnk refers to “Flanking Active TSS” and Enh refers to “Enhancers.”





^C Chromatin state from the HaploReg database which uses the 25-state model using 12 imputed marks. TxReg refers to “Transcribed and regulatory (Prom/Enh)”, EnhA1 refers to “Active Enhancer 1”, EnhAF refers to “Active Enhancer Flank”, and PromD1 refers to “Promoter Downstream TSS 1.”

^D Histone modification annotation of type H3K4me1. Enh refers to Enhancer.



^E Histone modification annotation of type H3K4me3. Pro refers to Promoter.

^F Histone modification annotation of type H3K27ac. Enh refers to Enhancer.

^G Histone modification annotation of type H3K9ac. Pro refers to Promoter.

A**B****C****D**

Adipocyte gene sets



All


Females

Males

$-\log_2(\text{permuted}_{10,000} \text{ p-value})$



A

Top 10 significant pathways in SAT vs VAT gene sets

**B****Pathway enriched adipocyte MGSS**

* = Predicted SREBF1 target genes

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.22.24317804>; this version posted November 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**D****C**